~ Buy the ZEGALOGUE (AUTOINJECTOR) (dasiglucagon hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

zegalogue (autoinjector) Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Zegalogue (autoinjector), and when can generic versions of Zegalogue (autoinjector) launch?

Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-three patent family members in twenty-four countries.

The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. Two suppliers are listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zegalogue (autoinjector)

Zegalogue (autoinjector) will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for zegalogue (autoinjector)?
What are the global sales for zegalogue (autoinjector)?
What is Average Wholesale Price for zegalogue (autoinjector)?

Summary for zegalogue (autoinjector)

International Patents:	33
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
DailyMed Link:	zegalogue (autoinjector) at DailyMed

Drug patent expirations by year for zegalogue (autoinjector)

Pharmacology for zegalogue (autoinjector)

Drug Class	Antihypoglycemic Agent
Mechanism of Action	Glucagon Receptor Agonists
Physiological Effect	Increased Glycogenolysis

US Patents and Regulatory Information for zegalogue (autoinjector)

zegalogue (autoinjector) is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting zegalogue (autoinjector)

Glucagon analogues
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING DIABETIC HYPOGLYCEMIA

FDA Regulatory Exclusivity protecting zegalogue (autoinjector)

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for zegalogue (autoinjector)

See the table below for patents covering zegalogue (autoinjector) around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Brazil	112015001451	análogos de glucagon	⤷ Sign Up
Japan	2022023029	グルカゴン類似体	⤷ Sign Up
Japan	2019187419	グルカゴン類似体 (GLUCAGON ANALOGS)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration